Randomized controlled trials have long been the gold standard for evaluating new therapies. But for pediatric brain tumors, it can be difficult–if not impossible–to enroll the large numbers of patients needed for these studies.
Randomized controlled trials have long been the gold standard for evaluating new therapies. But for pediatric brain tumors, it can be difficult–if not impossible–to enroll the large numbers of patients needed for these studies.
Designed by doctors. Powered by AI.
Owned by you.